Metastatic melanoma moves on: translational science in the era of personalized medicine.
Progress in understanding and treating metastatic melanoma is the result of decades of basic and translational research as well as the development of better in vitro tools for modeling the disease. Here, we review the latest therapeutic options for metastatic melanoma and the known genetic and non-genetic mechanisms of resistance to these therapies, as well as the in vitro toolbox that has provided the greatest insights into melanoma progression. These include next-generation sequencing technologies and more complex 2D and 3D cell culture models to functionally test the data generated by genomics approaches. The combination of hypothesis generating and hypothesis testing paradigms reviewed here will be the foundation for the next phase of metastatic melanoma therapies in the coming years.
Department of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland. Mitchell.Levesque@usz.ch.
Mitchell P
MP
Levesque
Department of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Phil F
PF
Cheng
Department of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Marieke I G
MI
Raaijmakers
Department of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Annalisa
A
Saltari
Department of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Reinhard
R
Dummer
D000818:Animals; D006801:Humans; D008545:Melanoma / Q000473:pathology* / Q000628:therapy*; D057285:Precision Medicine / Q000379:methods*; D057170:Translational Research, Biomedical / Q000379:methods*
3D culture; Bioengineered skin; Melanoma; Melanoma treatment; Skin reconstructs; Translational research